Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group.
In the present study the cross-resistance rates of cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group were compared with regard to beta-lactam-beta-lactamase inhibitor combinations and clindamycin. Piperacillin-tazobactam was the most active agent tested with an overall resistance rate of 0.2% and no resistance among cefoxitin-resistant strains. Ticarcillin-clavulanate was the least active combination with an overall resistance rate of 1.6% but a resistance rate of 13.1% among cefoxitin-resistant strains. For ampicillin-sulbactam, amoxicillin-clavulanate, and clindamycin resistance, rates of cefoxitin-resistant versus cefoxitin-susceptible strains were 9.1% and 0.4%, 8.3% and 0.9%, and 28% and 12.9%, respectively.
Aldridge
K E
KE
Department of Medicine, Louisiana State University Medical Center, New Orleans 70112.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001439:Bacteroides / Q000187:drug effects*; D001442:Bacteroides Infections / Q000382:microbiology; D001441:Bacteroides fragilis / Q000187:drug effects*; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000494:pharmacology; D002981:Clindamycin / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D006801:Humans; D008826:Microbial Sensitivity Tests; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D000078142:Tazobactam; D065093:beta-Lactamase Inhibitors
D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid; D002981:Clindamycin; D010397:Penicillanic Acid; D000078142:Tazobactam